ducovest

QLD:ARCA-ProShares Ultra QQQ

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 103.43

Change

+0.57 (+0.55)%

Market Cap

USD 0.88B

Volume

0.60M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the NASDAQ-100 Index?. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index, a modified market capitalization-weighted index, includes 100 of the largest non-financial domestic and international issues listed on the NASDAQ Stock Market. The fund is non-diversified.

Company Website : www.proshares.com

Currency: USD

Country : USA

Inception Date: 19/06/2006

Primary Benchmark: NASDAQ 100 TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.01%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

-0.25 (-0.49%)

 N/A

ETFs Containing QLD

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 53.94% 97% N/A 95% A
Dividend Return 0.16% 3% F 2% F
Total Return 54.09% 95% A 95% A
Trailing 12 Months  
Capital Gain 9.36% 61% D- 79% B-
Dividend Return 0.15% 3% F 1% F
Total Return 9.51% 55% F 72% C
Trailing 5 Years  
Capital Gain 252.04% 100% F 98% N/A
Dividend Return 1.11% 37% F 5% F
Total Return 253.15% 100% F 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 29.48% 92% A 83% B
Dividend Return 29.61% 91% A- 83% B
Total Return 0.13% 17% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 26.80% 61% D- 51% F
Risk Adjusted Return 110.47% 97% N/A 95% A
Market Capitalization 0.88B 95% A 63% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.